Novartis Aims For 14 New Blockbuster Drugs By End Of 2017
This article was originally published in The Pink Sheet Daily
Executive Summary
At an investor day presentation Nov. 8, Novartis discussed a pipeline expected to yield 18 regulatory decisions over the next 24 months. The Swiss pharma currently has 139 ongoing pipeline projects, including 73 NMEs.